文献速递膀胱癌与上尿路尿路上皮癌

肝细胞生长因子-MET-基质金属蛋白酶1信号在膀胱癌侵袭与增殖中的作用及MET抑制剂卡博替尼(XL184)对膀胱癌细胞的影响

The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
PubMed 文献 · Urology · 2016-12-21

本研究探讨肝细胞生长因子(HGF)-MET-基质金属蛋白酶1(MMP1)信号在膀胱癌(BCa)侵袭与增殖中的作用,并观察MET抑制剂卡博替尼(XL184)对膀胱癌细胞的影响。结果显示卡博替尼可抑制细胞增殖与侵袭(细胞指数:模拟组1.49 vs HGF组2.26 vs HGF+XL184组1.47,P<.05),并抑制HGF诱导的MMP1表达。作者认为卡博替尼可能对未来肌层浸润性膀胱癌的治疗有用。

要点

  • 5株膀胱癌细胞系中4株高表达MET,5637与T24细胞MET蛋白表达尤其高。
  • 卡博替尼抑制膀胱癌细胞增殖与侵袭(细胞指数:模拟组1.49 vs HGF组2.26 vs HGF+XL184组1.47,P<.05)。
  • 卡博替尼通过阻断HGF-MET信号抑制MMP1表达,作者认为其可能对未来肌层浸润性膀胱癌治疗有用。

核心结论

  • 卡博替尼通过阻断HGF-MET信号抑制MMP1表达,HGF-MET-MMP1信号参与膀胱癌细胞的侵袭与增殖。
  • 作者认为卡博替尼可能对未来肌层浸润性膀胱癌的治疗有用。

研究设计与样本

  • 体外研究:先用Western blot分析膀胱癌细胞系中MET表达,再用MTT与Matrigel侵袭实验(xCELLigence系统)检测卡博替尼对增殖与侵袭能力的影响。
  • 对5637细胞在有或无HGF刺激、有或无卡博替尼条件下进行基因表达谱分析与实时聚合酶链反应分析。

主要发现

  • 5株膀胱癌细胞系中4株高表达MET,5637与T24细胞MET蛋白表达尤其高。
  • 卡博替尼抑制细胞增殖与侵袭(细胞指数:模拟组1.49 vs HGF组2.26 vs HGF+XL184组1.47,P<.05)。
  • 基因表达谱分析显示加入HGF后基质金属蛋白酶1(MMP1)mRNA水平显著升高。
  • 卡博替尼抑制5637与T24细胞中HGF诱导的MMP1表达。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clarify the invasive mechanisms of muscle-invasive bladder cancer (BCa) would be useful for the determination of appropriate treatment strategies. We previously showed that hepatocyte growth factor (HGF)-MET signaling is correlated with invasiveness of BCa cells. Here, we investigated the effects of the MET inhibitor, cabozantinib (XL184), on BCa cells. METHODS: We first conducted Western blot analysis to investigate MET expression in BCa cell lines. Next, we examined the effect of cabozantinib on their proliferation and invasive abilities using MTT and Matrigel invasion assays, respectively. Invasion assays were performed using the xCELLigence system. Additionally, to investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles and performed real-time polymerase chain reaction analyses of 5637 cells that were cultivated with or without HGF stimulation, with or without cabozantinib. RESULTS: MET was highly expressed in 4 of 5 BCa cell lines, and 5637 and T24 cells showed especially high protein expression of MET. Cabozantinib suppressed cell proliferation and invasion (cell index; mock, 1.49 vs HGF, 2.26 vs HGF + XL184, 1.47, P < .05). Gene expression profile analysis indicated that matrix metalloproteinase 1 (MMP1) was significantly elevated at the mRNA level with addition of HGF. Moreover, cabozantinib suppressed HGF-induced MMP1 expression in 5637 T24 cells. CONCLUSIONS: These data indicate that cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Shintani T, Kusuhara Y, Daizumoto K, et al. The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells. Urology. 2016. PMID: 28013036. doi:10.1016/j.urology.2016.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。